TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02254733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Description: CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
Study: NCT03424057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Karydakis technique.
Description: In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method
Study: NCT02254733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assertive Community Treatment (ACT)
Description: Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
Study: NCT04120168

Intervention type: GENETIC
Intervention: Laboratory Tests
Description: * Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~* Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication.
Study: NCT01171885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml of Ropivacaine 0.5%.
Study: NCT02183558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OGTT by randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OGTT by indication
Study: NCT03807479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: 2 film-coated tablets à 15mg for oral administration on a daily basis
Study: NCT00728260

Intervention type: BIOLOGICAL
Intervention: None administered in this study
Description: N/A in this study
Study: NCT03273413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablet
Study: NCT03850470

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical examination
Description: Thorough examination including history, screening, motion testing, strength testing, special testing

Intervention type: OTHER
Intervention: MRI
Description: Low field MRI .25 Tesla
Study: NCT02057133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Administered orally.
Study: NCT03141359

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Primary tumor SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: concurrent chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: concurrent chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis Platinum
Description: concurrent chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: concurrent chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: mediastinal radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: adjuvant immunotherapy
Study: NCT04466241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet
Description: 2 tablets morning and evening from Day 1 to Day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet
Description: 2 tablets morning and evening from Day 1 to Day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet
Description: 2 tablets morning and evening from Day 1 to Day 10
Study: NCT00745251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 15 mg Phentermine and 92 mg Topiramate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00924066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixempra (Ixabepilone (BMS-247550) )
Description: Participants received Ixabepilone 6mg/m\^2 for a total of 30mg/m\^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
Study: NCT04466241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40Mg Oral Tablet
Description: 1 tablet daily from Day 1 to Day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 Mg Oral Tablet
Description: 1 tablet daily from Day 1 to Day 10
Study: NCT02057133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Administered orally.
Study: NCT02666430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan's insulin glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Study: NCT02011594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg Q2W intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT02057133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Administered orally.
Study: NCT03681002

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: structured lifestyle program
Description: Intensive Lifestyle counseling during one year
Study: NCT02933996

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS+GA group
Description: The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
Study: NCT01818570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPC-5650
Description: A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
Study: NCT01391182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EACA
Description: EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
Study: NCT05271201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill exercise (mild)
Description: mild intensity treadmill training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill exercise (moderate)
Description: moderate-intensity treadmill training
Study: NCT00084539

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT01577537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: Vaginal gel, daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal gel, daily for 7 days
Study: NCT02057133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV infusion.
Study: NCT04014400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suprathel or Xeroform donor site application
Description: The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suprathel or Xeroform donor site application
Description: The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
Study: NCT02727140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga with Asana (yoga postures)
Description: Yoga intervention consisting of asana, breathing and relaxation, meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga without Asana (yoga postures)
Description: Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
Study: NCT03237585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rural response system (RRS) intervention to reduce violence against women
Description: The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
Study: NCT01617733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: 4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
Study: NCT04605419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
Study: NCT02462070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Lotion
Study: NCT02057133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administered IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administered IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Endocrine therapy administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Endocrine therapy administered orally.
Study: NCT03581058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
Study: NCT03447561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipatory + consummatory food reward
Description: Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consummatory food reward
Description: Exposure to consummatory food reward (drinking sips of chocolate milkshake).
Study: NCT04324970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tookie Vest
Description: Tookie Vest
Study: NCT01514266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin+Bioprine
Description: The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02761369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A multi-channel deep TMS device with an H-coil (Brainsway Ltd)
Description: A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A multi-channel deep TMS device with an H-coil (Brainsway Ltd)
Description: A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
Study: NCT03019601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Education
Description: Structured group education on family planning facilitated by Peer Champions
Study: NCT01620190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study: NCT01247051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precoating
Description: preoperative filling of heart lung machine with patients blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard priming
Description: preoperative filling of heart lung machine with colloids
Study: NCT00002837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT02761369

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: A multi-channel deep TMS device with an H-coil (Brainsway Ltd)
Description: A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
Study: NCT02144259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA immediately postpartum
Description: DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
Study: NCT00002837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Study: NCT02463851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVAC GOLD multielectrode catheter
Description: Cardiac ablation for Atrial Fibrillation
Study: NCT02144259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implanon immediately postpartum
Description: Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
Study: NCT02463851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Force single-tip ablation catheter
Study: NCT02346539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Single Acute dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine polacrilex
Description: Single Acute dose
Study: NCT01464359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: On Day 8 pre-transplant, start hydration with allopurinol per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: On Days 7, 6 and 5 pre-transplant, 25 mg/m\^2 intravenously over 1 hour.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if \<12 kg) intravenously every 6 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m\^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source.
Study: NCT04003870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CASO
Description: Customized arch support orthoses (CASO)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HL
Description: Orthotic Heel Lift (HL)
Study: NCT03370484

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Water with 80 mg sucralose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk mineral supplement
Description: Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
Study: NCT01626885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214
Description: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214